Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00089804 · ClinicalTrials.gov registry record · Phase 3
Study of LJP 394 in Lupus Patients With History of Renal Disease
A Phase 3 study, sponsored by La Jolla Pharmaceutical Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 943
- Enrollment target
NCT00089804: Clinical Trial Phase 3 study, sponsored by La Jolla Pharmaceutical Company.
NCT00089804 is a Phase 3 study that was terminated before completion, run by La Jolla Pharmaceutical Company. The registered enrollment target is 943 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00089804, a Phase 3 study, was terminated before completion, sponsored by La Jolla Pharmaceutical Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 943 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether abetimus sodium is more effective than placebo in delaying time to renal flare in SLE patients with a history of renal disease.
Interventions
- DRUG abetimus sodium (LJP 394) and/or placebo solution
- DRUG abetimus sodium (LJP 394)
- DRUG Phosphate-buffered saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 943 participants |
| Start Date | 2004-10 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Why NCT00089804 stopped before completion
NCT00089804 is an interventional study that assigns participants to a tested intervention. The registered 943 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% higher).
The record links to 0 conditions, and to 3 interventions - of which abetimus sodium (LJP 394) and/or placebo solution is the first listed.
NCT00089804 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00089804 about?
NCT00089804 is a clinical study titled "Study of LJP 394 in Lupus Patients With History of Renal Disease". The primary purpose of this study is to determine whether abetimus sodium is more effective than placebo in delaying time to renal flare in SLE patients with a history of renal disease.
What is the current status of trial NCT00089804?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 943 participants. The study started on 2004-10. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00089804?
The interventions under investigation include: abetimus sodium (LJP 394) and/or placebo solution (DRUG), abetimus sodium (LJP 394) (DRUG), Phosphate-buffered saline (DRUG).
Who is sponsoring clinical trial NCT00089804?
This trial is sponsored by La Jolla Pharmaceutical Company, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00089804's enrollment target sits among peer trials
943 335th of 2000 higher than 1,666 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia